MENU ABOUT US MAKE A DONATION
The Epoch Times
Login
SEARCH
CLOSE
Help Center subscribe newsletter Newsstands Epoch Shop Gift
  • TOP NEWS
  • SPECIAL SERIES
  • SPECIAL COVERAGE
  • LATEST ARTICLES
  • US
    • US News
    • US Features
    • US Politics
    • US Crime News
    • New York
    • San Francisco
    • Los Angeles
  • Opinion
    • Thinking About China
    • Viewpoints
    • Unbridled Evil: The Corrupt Reign of Jiang Zemin in China
    • The Reader’s Turn
  • China News
    • US-China Relations
    • Chinese Regime
    • Business & Economy
    • Chinese Culture
    • China Human Rights
    • Social Issues
    • Organ Harvesting in China
  • World News
    • Africa News
    • Americas
    • Asia & Pacific
    • Canada
    • Europe
    • UK News
    • Australia News
    • International
    • Middle East
  • Business & Markets
    • Companies
    • Economy
    • Markets
    • Real Estate
    • Gold and Commodities
  • ARTS & CULTURE
    • Fine Arts & Craftsmanship
    • Performing Arts
    • Books
    • Traditional Culture
    • Shen Yun Special Coverage
    • Film & TV
  • Science
    • News
    • Space
    • Environment
  • Tech
    • Tech News
    • Tech Products & Reviews
    • Social Media
  • Sports
  • Videos
    • American Thought Leaders
    • China Insider
    • Crossroads
  • Bright
    • Lifestyle
    • Inspired
    • Family & Education
    • Personal Finance
    • American Essence
  • Entertainment
    • Film & TV
    • Entertainment News
  • Health
    • Experts
    • Conditions
    • Life & Wellness
  • Special Topics
    • Battlefields
SEARCH
  • EpochTV
  • US
  • US Politics
  • Opinion
  • World News
  • China
  • Hong Kong
  • Health
  • Bright
  • Arts
  • Falun Gong
  • Premium
  • Markets
  • Games
  • Livestream
  • More

emergency approval

  • Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint
    Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint
    Japanese pharmaceutical company Shionogi's new oral COVID-19 drug has achieved the primary endpoint in a clinical trial, the company announced in September. From February to July, Shionogi conducted a clinical ...
    November 18, 2022BY Ellen Wan and Angela Bright
TOP NEWS
  • Gold, Silver Suffer Sharp Selloff After Warsh Speech in Jackson Hole
    6hr By Andrew Moran
    Gold, Silver Suffer Sharp Selloff After Warsh Speech in Jackson Hole
  • US Forces Sink Vessel Providing At-Sea Refueling for Cartel: SOUTHCOM
    7hr By Ryan Morgan
    US Forces Sink Vessel Providing At-Sea Refueling for Cartel: SOUTHCOM
  • US Updates Travel Advisories for 5 Middle East Countries
    8hr By Naveen Athrappully
    US Updates Travel Advisories for 5 Middle East Countries
  • Right-Wing Commentator Milo Yiannopoulos Deported to UK After ICE Arrest
    10hr By Jacki Thrapp
    Right-Wing Commentator Milo Yiannopoulos Deported to UK After ICE Arrest
  • Here’s What Darwin’s Theory Can’t Explain | Michael Behe
    10hr By Jan Jekielek, Epoch TV
    Here’s What Darwin’s Theory Can’t Explain | Michael Behe
  • Trump Admin Blocks $1.6 Billion in Potentially Fraudulent Medicare Lab Bills
    11hr By Naveen Athrappully
    Trump Admin Blocks $1.6 Billion in Potentially Fraudulent Medicare Lab Bills
  • Something in the Environment Could Be Driving Up Autism
    12hr By Marina Zhang
    Something in the Environment Could Be Driving Up Autism
  • IV Fluids From 2 Companies Recalled Due to Particulate Matter
    13hr By Naveen Athrappully
    IV Fluids From 2 Companies Recalled Due to Particulate Matter
  • Former White House Teleprompter Operator Ordered to Pay $172,000 in Insider Trading Case
    14hr By Kimberly Hayek
    Former White House Teleprompter Operator Ordered to Pay $172,000 in Insider Trading Case
  • Universities Could Lose Foreign-Student Certification Over Internship Rule Violations, Trump Admin Says
    16hr By Kimberly Hayek
    Universities Could Lose Foreign-Student Certification Over Internship Rule Violations, Trump Admin Says
The Epoch Times
Copyright © 2000 - 2026 The Epoch Times Association Inc. All Rights Reserved.
Back Top